Does Group Health Cooperative (GHC) Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), the key protein driving osteoclast-mediated bone resorption. The FDA approved it on June 1, 2010, for postmenopausal women at high risk of fracture, and later extended that approval to men with osteoporosis, patients on glucocorticoid therapy, and patients receiving androgen-deprivation or aromatase-inhibitor therapy [1]. It is given as a 60 mg subcutaneous injection every six months, typically in a clinic setting.

The Clinical Evidence Behind Prolia

The FREEDOM trial (N=7,868) compared denosumab 60 mg to placebo over 36 months in postmenopausal women with a lumbar spine or total hip T-score between -2.5 and -4.0. Denosumab reduced new vertebral fractures by 68% (relative risk 0.32, 95% CI 0.26-0.41, P<0.001), hip fractures by 40%, and nonvertebral fractures by 20% compared to placebo [2]. These are among the largest fracture-reduction effect sizes published for any osteoporosis medication.

The FREEDOM Extension study followed participants for up to 10 years of continuous denosumab therapy and found sustained bone mineral density gains without evidence of a therapeutic ceiling [3]. Both datasets are frequently cited by payers, including GHC-affiliated plans, when setting coverage criteria.

How Prolia Differs From Bisphosphonates

Oral bisphosphonates such as alendronate (Fosamax) sit on Tier 1 or Tier 2 on almost every formulary and cost less than $15 per month generic. Prolia occupies a higher tier because it is a biologic, requires cold-chain storage, and must be administered by a healthcare professional. Payers including GHC generally require documented failure of, contraindication to, or intolerance of bisphosphonate therapy before approving Prolia [4].

How GHC Plans Are Structured

Group Health Cooperative operates as a consumer-governed nonprofit health plan in Washington State and parts of Idaho. GHC offers commercial group insurance, individual and family plans, Medicare Advantage plans (including their PEBB and SEBB contracts with Washington State), and Medicaid managed care products. Each product line has its own formulary and prior authorization (PA) requirements.

Commercial vs. Medicare Advantage Formularies

Commercial GHC plans typically use a 3-to-5-tier formulary. Prolia generally lands on Tier 3 (preferred brand) or Tier 4 (non-preferred specialty), with copays ranging from $50 to $200 per administration depending on the plan year and your specific benefit design. Under Medicare Advantage (MA) plans administered by GHC, Prolia is usually billed under Part B rather than Part D because a provider administers the drug in-office under HCPCS code J0897. Under Part B benefit rules, Medicare pays 80% of the allowed amount after the Part B deductible ($240 in 2024), and the plan's supplemental benefit covers part of the remaining 20% [5].

The Prior Authorization Process

GHC, like most insurers, requires PA for Prolia across most plan types. The standard PA criteria align closely with the 2022 American Association of Clinical Endocrinology (AACE) guidelines, which recommend pharmacological therapy for postmenopausal women with [6]:

• A hip or vertebral fracture (any T-score)
• T-score <-2.5 at the lumbar spine or femoral neck
• T-score between -1.0 and -2.5 plus a 10-year FRAX hip fracture probability >3% or major osteoporotic fracture probability >20%

Your prescriber will typically submit clinical documentation including a recent DEXA scan (within 12-24 months), FRAX score, fracture history, and evidence that bisphosphonate therapy was tried and failed or is contraindicated.

Step-by-Step: Getting GHC to Cover Prolia

The path from prescription to covered injection involves several specific steps. Skipping any one of them is the most common reason for delays or denials.

Step 1: Verify Formulary Placement

Call the member services number on the back of your GHC insurance card or log into your member portal. Ask specifically: "Is denosumab 60 mg injection (Prolia, NDC 55513-730-01) covered under my benefit, and under which tier?" Get a reference number for the call. Formularies can change on January 1 each year, so a check performed in December may not reflect January coverage.

Step 2: Confirm the Correct Billing Pathway

Prolia administered in a physician's office or infusion center is billed as a medical benefit (Part B analog for commercial plans), not as a pharmacy benefit. This distinction matters because your pharmacy deductible does not apply. Instead, your medical deductible and out-of-pocket maximum govern the cost. Ask GHC whether the drug will be purchased through the provider's buy-and-bill arrangement or through a specialty pharmacy.

Step 3: Submit the Prior Authorization

Your prescribing physician's office typically initiates the PA. The documentation package should include:

• DEXA scan report with T-scores at spine and hip
• FRAX 10-year fracture probability calculation
• Documentation of prior bisphosphonate use (dates, doses, reason for discontinuation) or contraindication rationale
• Relevant lab results (serum calcium, vitamin D level, creatinine)
• ICD-10 diagnosis codes (M81.0 for age-related osteoporosis without fracture, or M80.xx for osteoporosis with fracture)

The AACE 2022 Clinical Practice Guideline explicitly states: "Denosumab is an appropriate first-line treatment option for patients at very high or imminent fracture risk, patients who cannot tolerate oral bisphosphonates, or patients with renal impairment (eGFR <35 mL/min/1.73 m²)" [6]. Quoting this language in the PA submission strengthens the clinical justification.

Step 4: Track the Decision Timeline

Washington State insurance regulations require health plans to respond to non-urgent PA requests within 5 business days and urgent (expedited) requests within 72 hours. If GHC does not respond within that window, your physician can escalate to a peer-to-peer review call, where the prescriber speaks directly with GHC's medical director or physician reviewer.

What Happens if GHC Denies Coverage?

Denial is not the end of the road. A significant proportion of denied prior authorizations are overturned on appeal. The Kaiser Family Foundation analysis of ACA marketplace plans found that 82% of denied claims that were appealed were ultimately paid [7]. GHC, as a Washington State-licensed insurer, is bound by the state's grievance and appeal rules under RCW 48.43.530.

Internal Appeal

File a formal internal appeal within 180 days of the denial notice. The appeal should include:

• A letter of medical necessity from your prescribing physician
• The FREEDOM trial data showing 68% vertebral fracture reduction [2]
• Any peer-reviewed literature supporting Prolia use in your specific clinical situation (renal impairment, prior bisphosphonate failure, etc.)
• The AACE 2022 guideline recommendation language cited above [6]

GHC must render a decision on a standard internal appeal within 30 days.

External Independent Review

If the internal appeal fails, Washington State law (RCW 48.43.535) entitles you to an external independent review by a state-certified Independent Review Organization (IRO). The IRO's decision is binding on GHC. External reviews succeed at meaningful rates: a 2023 analysis published in Health Affairs found that patients won approximately 39-75% of external reviews depending on the clinical category [8].

Expedited Appeals for Urgent Situations

Patients who have already been on Prolia and face a mid-therapy denial face a particular clinical risk. Discontinuing denosumab without transitioning to a bisphosphonate causes rapid bone loss and a documented rebound vertebral fracture risk. The ENDURE trial and post-marketing surveillance data show that the risk of multiple vertebral fractures spikes within 7-18 months of stopping denosumab without antiresorptive follow-up [9]. This clinical urgency supports filing an expedited appeal, which GHC must resolve within 72 hours.

Cost-Sharing and Financial Assistance Options

Even with coverage, the 20% coinsurance on a $1,600 drug adds up to $320 per injection, or $640 per year. Several programs can reduce this burden.

Amgen's Prolia SupportPlus Program

Amgen (the manufacturer) offers a co-pay assistance card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per dose for eligible patients. As of 2024, the program covers up to $3,500 per calendar year. Medicare and Medicaid patients are not eligible for manufacturer co-pay cards under federal anti-kickback rules, but they may qualify for Amgen's patient assistance program (Amgen Safety Net Foundation) if income is below 500% of the federal poverty level [10].

Medicare Patients: The Part B 20% Exposure

Under traditional Medicare and most GHC Medicare Advantage plans, the remaining 20% after Part B pays is your responsibility. For a drug reimbursed at roughly $1,300 per dose (the 2024 Medicare allowed amount for J0897), that 20% equals approximately $260 per dose. Supplemental coverage through a Medigap plan (for traditional Medicare members) or the plan's out-of-pocket maximum (for Medicare Advantage members) may cap this exposure.

Biosimilar Alternatives: A Cost-Reduction Path

The FDA approved the first denosumab biosimilars in 2024. Jubbonti and Wyost (both denosumab-bbdz, Sandoz) received FDA approval and are therapeutically equivalent to Prolia for approved indications [11]. GHC formularies may preferentially list a biosimilar over Prolia as lower-tier alternatives become commercially available. Biosimilar pricing is typically 15-35% below the reference biologic list price, and plans frequently offer better cost-sharing on biosimilar tiers to steer utilization.

Clinical Criteria GHC Reviewers Typically Apply

The following framework reflects the standard clinical thresholds that GHC physician reviewers and most commercial payers apply when evaluating Prolia PA requests, synthesized from the AACE 2022 guidelines [6], the NOF Clinician's Guide [4], and standard payer policy language.

| Clinical Scenario | Typical PA Approval Likelihood | Key Documentation Needed | |---|---|---| | T-score <-2.5 plus prior fragility fracture | High | DEXA, fracture imaging, FRAX | | T-score <-2.5 alone, bisphosphonate failure | High | DEXA, prior Rx records, intolerance documentation | | T-score <-2.5 alone, bisphosphonate naive | Moderate | DEXA, FRAX >20% major or >3% hip | | T-score between -2.0 and -2.5, no fracture | Low-Moderate | FRAX, secondary risk factors, specialist letter | | eGFR <35 mL/min/1.73 m² (bisphosphonate contraindicated) | High | Lab values, nephrology note | | On glucocorticoid therapy >3 months at >5 mg/day prednisone equivalent | Moderate-High | Medication list, DEXA, rheumatology or pulmonology note |

Monitoring Requirements That Support Ongoing Coverage

Coverage approval for the first injection does not guarantee automatic renewal. GHC may require periodic re-authorization, typically every 12-24 months. Submitting the following documentation proactively reduces the chance of a gap in therapy.

Repeat DEXA Scanning

The NOF recommends repeat DEXA scanning every 1-2 years during active pharmacotherapy [4]. A repeat scan showing stable or improved bone mineral density documents treatment response and supports continued medical necessity. If BMD declines despite therapy, that finding supports escalation to anabolic therapy (teriparatide or romosozumab) rather than continuation of Prolia, and GHC's reviewer will likely flag this for clinical discussion.

Calcium and Vitamin D Adequacy

The FDA label for Prolia requires that patients receive adequate calcium and vitamin D supplementation to reduce the risk of hypocalcemia [1]. GHC reviewers and pharmacist reviewers may check that a calcium supplement (typically 1,000-1,200 mg daily from diet plus supplement) and vitamin D (800-1,000 IU daily, or higher if 25-OH vitamin D level is below 30 ng/mL) are co-prescribed. Missing these co-prescriptions can trigger a clarification request that delays renewal authorization.

Dental Clearance Documentation

Osteonecrosis of the jaw (ONJ) is a rare but recognized adverse event with denosumab, with an estimated incidence of 1-2% in oncologic doses and substantially lower (roughly 0.001-0.01%) in osteoporosis doses [1]. Some GHC reviewers request a dental clearance note before initiating therapy, particularly for patients with recent tooth extraction, active periodontal disease, or planned invasive dental procedures. Including a dental note in the initial PA package removes a common reason for delay.

Special Populations and Coverage Nuances

Men With Osteoporosis

Prolia received FDA approval for men with osteoporosis at high fracture risk in 2012 [1]. GHC covers this indication but may apply more stringent PA criteria because the baseline fracture risk in men is lower and because alendronate (generic) is inexpensive and effective. A T-score <-2.5 at either the lumbar spine or femoral neck in a male patient with documented secondary causes (hypogonadism, glucocorticoid use, prior fracture) generally satisfies GHC's medical necessity criteria.

Patients on Androgen Deprivation Therapy (ADT) for Prostate Cancer

ADT accelerates bone loss at a rate of 2-3% per year at the femoral neck [12]. The FDA approved denosumab (as Prolia) to increase bone mass in men at high fracture risk receiving ADT for nonmetastatic prostate cancer. GHC's oncology PA pathway is often faster than the standard osteoporosis pathway. Urologists and oncologists should specify the ADT indication explicitly in the PA request rather than using a generic osteoporosis code.

Patients on Aromatase Inhibitor (AI) Therapy for Breast Cancer

Women receiving AI therapy experience bone loss of 1-3% per year [13]. GHC follows ASCO/ONS guidelines that recommend bone-modifying agents for patients on AI therapy with a T-score <-2.0 or a T-score between -1.0 and -2.0 plus additional risk factors [13]. The oncology PA pathway typically applies here as well, and a breast oncologist's supporting letter carries significant weight with GHC's reviewer.

What to Do Before Your First Injection: A Practical Checklist

1. Call GHC member services and confirm Prolia (or denosumab biosimilar) formulary status for the current plan year.
2. Ask your prescribing physician's office to initiate PA at least 3-4 weeks before the planned injection date.
3. Ensure a current DEXA scan (within 12-24 months), FRAX calculation, and lab results (calcium, vitamin D, creatinine) are in the chart.
4. Confirm your calcium and vitamin D supplements are documented in the prescription record.
5. Schedule a dental visit if you have not had one in the past 6 months and notify your dentist you are starting an antiresorptive agent.
6. If commercially insured, enroll in Amgen's SupportPlus co-pay program at ProliaCopay.com before the injection.
7. If the PA is denied, ask the office to request a peer-to-peer review within 5 business days rather than waiting for a standard written denial.

The AACE 2022 guideline panel notes: "Delay in initiating pharmacotherapy for very-high-risk patients represents a missed opportunity to prevent fractures that carry a 20% one-year mortality risk in the case of hip fractures" [6]. Getting the administrative steps right the first time is the fastest route to protected bone.